In univariable analysis, statin users were more likely to be male (p<0.001), had a higher frequency of metabolic syndrome (p<0.001), diabetes type 2 (p<0.001), MAU (p<0.001), ACE-i/ARB treatment (p<0.001), and previous cardiovascular events (p<0.001), were older (p<0.001), had larger BMI (p<0.001), lower diastolic blood pressure (p = 0.02), higher fasting glucose (p<0.001), serum uric acid (p = 0.004), and triglycerides (p = 0.003), had lower levels of LDL (p<0.001) and HDL cholesterol (p = 0.001) compared to patients not taking statins (tables 1 and 2). Here, ACE is linked to metabolic syndrome.